Skip to content
Medical Health Aged Care

QPS Launches New Leukopak and Cell Therapy Products Facility

QPS Holdings, LLC 3 mins read

Clinical Research Supports Economic Growth and Development, While Making a Global Difference


SPRINGFIELD, Mo.--BUSINESS WIRE--

QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the opening of a new Leukopak collection and blood product processing center. This facility is designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. QPS is a full service CRO that’s dedicated to supporting drug development from conceptualization through to commercial launch. This facility is providing critical raw materials for the research and development of cell therapies but will soon be supporting clinical and commercial cell therapy companies and patients. In addition, this new facility will support the local economy by providing stipends to blood product donors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113328476/en/

The new QPS Cell Therapy Unit in Springfield, Missouri is a Leukopak collection and blood product processing center designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. (Photo: Business Wire)

The new QPS Cell Therapy Unit in Springfield, Missouri is a Leukopak collection and blood product processing center designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. (Photo: Business Wire)

To build out the facility and ensure the success of this new venture, QPS has hired Tia Hexom, PhD, (Senior Director of Cell Therapy Services and Manufacturing). With over a decade of experience in the cell therapy field, Hexom is excited to be building cell therapy capabilities in the Midwestern United States.

QPS Missouri is a division of QPS Holdings LLC, a global Clinical Research Organization (CRO) that conducts studies on behalf of pharmaceutical and biotech companies for the development of new and existing pharmaceutical products. This new Leukopak and Cell Therapy products donation and processing center will be housed in the same building as the new, state-of-the-art Screening and Recruitment Center that opened in July 2022, located at 2025 W. Sunshine Street, Springfield, MO. Study participants and blood product donors are paid a stipend for their participation in these Clinical Research activities. These stipends benefit the study participants and donors and, therefore, the local economy.

“Our participants and donors are a key part of the success of QPS in Springfield, Missouri and they continue to make a difference by helping advance drug development research,” states Brendon Bourg, Vice President, Early Phase Clinical/Head of Administration QPS Missouri. “To have the opportunity and ability to provide this type of supplemental income to our local community, while providing a valuable service to our pharmaceutical and biotech clients is something we (QPS) are honored to be a part of.”

Located in Springfield, QPS Missouri has been conducting clinical research studies for over 30 years, with the help of more than 50,000 study participants. In addition to the new Cell Therapy facilities, the Springfield campus houses five independent clinics with more than 240 beds, a pharmacy with a retention area, local and central CAP/CLIA safety lab, a clinical trial kit processing area, and a 2,500 square foot negative pressure room.

QPS has always been on the front line of clinical research in all areas of pharmaceutical and biotech drug development. Since opening its doors in Springfield in 1994, QPS Missouri has conducted more than 2,000 Phase I FDA-regulated studies and paid over $50 million to local participants and donors.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, cell therapy products (such as Leukopaks and PBMCs), clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I clinical facilities, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.


Contact details:

Gabrielle Pastore, QPS Marketing
Phone: 302-287-7821
Email: gabrielle.pastore@qps.com
Website: www.qps.com

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2024
  • 07:05
Royal Australian College of GPs

GPs key to addressing Australia’s mental health crisis: RACGP

Patients must have greater funding for mental health care from their GP, as reporting in The Australian that quantifies the severe shortfall of mental health support and the failure of Australia’s mental health system makes clear. This call from the from the Royal Australian College of GPs (RACGP) comes ahead of a soon-to-be-released report that shows an $8 billion shortfall in funding for healthcare including general practice, social services, and housing by immediate past AMA President Professor Steve Robson and ANU head of psychiatry Associate Professor Jeffrey Looi. The RACGP has long called on the Government to address funding and…

  • Contains:
  • Medical Health Aged Care
  • 06/12/2024
  • 22:55
EssilorLuxottica Media Relations

OneSight EssilorLuxottica Foundation Joins Forces with World Health Organization to Advance Global Vision Care Under WHO SPECS 2030 Initiative

OneSight EssilorLuxottica Foundation Joins Forces with World Health Organization to Advance Global Vision Care Under WHO SPECS 2030 Initiative Paris, France and Geneva, Switzerland (6 December 2024) – The OneSight EssilorLuxottica Foundation is proud to announce its collaboration with the World Health Organization (WHO) as a global collaborating partner on the WHO’s SPECS 2030 initiative.The SPECS initiative builds on the world’s first-ever global target to increase effective refractive error coverage by 40% by 2030, which was endorsed by WHO Member States in 2021 at the World Health Assembly. This collaboration between WHO and the Foundation represents a significant step forward in addressing…

  • Medical Health Aged Care, Political
  • 06/12/2024
  • 16:24
Massage & Myotherapy Australia

ANZSCO’s response to Massage & Myotherapy Australia recommended reforms welcomed

Massage & Myotherapy Australia has welcomed reforms to the Australian Bureau of Statistics’ OSCA (formerly ANZSCO) Occupation Standard Classification for Australia list for Massage Therapists 411613. Mrs Ann Davey CEO, said that the long overdue reforms to the old ANZSCO listing, now recognise the three distinct Australian massage occupations. This includes the new Unit Group of 4412 Massage Therapists and Myotherapists, with the three subcategories of 441231 Massage Therapist, 441232 Myotherapist, and 441233 Remedial Massage Therapist. Mrs Davey said, ‘We welcome these changes, because they represent the significant changes in professionalism, training and competency standards that have occurred over the…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.